🔗 Share this article

While the United States continues making historic revisions to its immunization recommendations, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccines throughout the pandemic and has focused upon potential deaths after COVID-19 immunization in her short position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Program

Public health authorities planned to reveal radical revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s immunization schedule, it is understood – a major change that would place the US out of alignment with much of the international standard with insufficient data for public health gain. The announcement has been delayed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A Shift at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for halting specific childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

In her initial statements, she has continued to focus on vaccines – typically the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Høeg has little discernible experience in drug development, regulation or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the CDER, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in industry regulation.”

Previous commissioners of CBER would “grasp regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Clearly, she has not acquired the sort of resume that former directors who ran CBER have had.”

This division has an immense range of responsibilities at the agency, Woodcock stated.

“The public just focuses on the new drug program, but the off-patent medication office authorizes thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and all of those have to be looked after,” Woodcock said. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the job, which supervises over 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” she concluded.

Official Statement and Disputed Programs

When asked about concerns about Høeg’s qualifications and whether this selection indicates increased cooperation among FDA leaders on immunizations, a press secretary said that the “concerns rely on incorrect assumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson explained, pointing to the period Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious one-day drug-approval program that allegedly worried her predecessors. “How are these medications being picked for this fast-track system? Who makes the choices?” Dr. Howard asked. “There is a lot of secrecy going on at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, aside from immunizations.”

Documented Track Record on Immunizations

Regarding immunizations, Høeg has a more documented, if concerning, past, critics observe. She released a analysis using unverified crowd-sourced reports to assess the rate of myocarditis following COVID-19 immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “policy goals” for the new government featured changing rules for new vaccines and ending “non-essential” vaccines, she said after the election on a audio program. At the agency, Høeg has reportedly proposed excluding adolescent males from getting COVID-19 vaccines.

“She is an thorough true believer who starts off with her preconceived notions and tailors the evidence to retrofit the science in a very deceptive, dishonest fashion,” Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|